Author Archives: yaoyan 姚艳

At the end of the first quarter of 2023, many pharmaceutical companies disclosed major adjustments to their R&D pipelines in their quarterly reports. Eli Lilly also announced they will give up on three clinical trials which include TRPA1 antagonist. Eli Lilly’s TRPA1 antagonist was acquired from Hydra Biosciences in 2018 and is mainly used for […]